Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | FAAH | O00519 | 6/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2207330 | 0.90 | MAPT (0.35) | MAPTFAAHMGLLTSHRLMNA | |
| SCHEMBL11599817 | 0.85 | MAPT (0.37) | MAPTFAAHTSHRCYP3A4TDP1 | |
| SCHEMBL2784436 | 0.83 | MAPT (0.38) | MAPTTSHRLMNAALDH1A1HPGD | |
| SCHEMBL7056636 | 0.81 | CYP1A2 (0.45) | MAPT | |
| SCHEMBL6848208 | 0.81 | MAPT (0.35) | MAPT | |
| SCHEMBL335124 | 0.80 | CHRM1 (0.41) | MAPTFAAHTDP1 | |
| SCHEMBL8342772 | 0.79 | TDP1 (0.39) | MAPTFAAHTSHRLMNAUSP2 | |
| SCHEMBL334795 | 0.78 | MAPT (0.44) | MAPTFAAHTSHRALDH1A1TDP1 | |
| SCHEMBL6910766 | 0.77 | CA2 (0.47) | MAPTFAAHTSHRCYP3A4TDP1 | |
| SCHEMBL28162523 | 0.77 | TSHR (0.39) | MAPTFAAHMGLLTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688891-B1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-9090628-B2 | Benzoxazepin compounds selective for PI3K P110 delta and methods of use | GENENTECH, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | GENENTECH, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-22 | — | — | US | disclosed |
| US-7981881-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| WO-2007096261-A2 | PROCESS FOR THE PREPARATION OF DIOXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| US-20070197615-A1 | Process for the preparation of the PPAR alpha agonist NS-220 | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20040142945-A1 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004043367-A2 | FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | MCL1, FPR1, LTC4S | MAPT 4840/4885FAAH 1258/4885MGLL 4248/4885 |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R4 | MAPT 2831/4885FAAH 941/4885MGLL 3386/4885 |
| US-20040142945-A1 | Fused heterocyclic compounds and use thereof | MCL1, NFATC1, BCR | MAPT 4828/4885FAAH 1253/4885MGLL 4360/4885 |
| US-20070197615-A1 | Process for the preparation of the PPAR alpha agonist NS-220 | PPARD, PPARA, PPARG | MAPT 4624/4885FAAH 517/4885MGLL 637/4885 |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | MCL1, FPR1, LTB4R | MAPT 4815/4885FAAH 1284/4885MGLL 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.